The supplements are intended to reduce urinary urgency, accidents, and day/night frequency in patients with overactive bladder and urinary infections.
MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.
"We look forward to FDA's review of our application for a potential new treatment option for the millions of people living with OAB," said Bernhardt Zeiher, MD, president of Development at Astellas.
"The use of acupuncture with or without clomiphene, compared with control acupuncture and placebo, did not increase live births," the authors write.
The supplement contains pumpkin seed and soy germ extract, and Synetrim CQ, a botanical that further promotes bladder control by aiding metabolic health and managing weight.
The researchers found that for treatment of overactive bladder, the safety and efficacy of intradetrusor injection of onabotulinumtoxin A is sensitive to injection volume and depth.
The researchers hypothesized that some antimuscarinics with "high lipophilicity, neutral polarity, or low molecular size still cross the blood-brain barrier and further affect neurotransmission in the brain," which could possibly trigger the depressive symptoms.
The approval was based on two 12-week, randomized, double-blind, placebo-controlled trials that included 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.
3M announced the launch of Cavilon Advanced Skin Protectant for the prevention of moderate to severe incontinence-associated dermatitis (IAD).
The Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee voted 14-4 in favor of the benefit risk profile of the New Drug Application (NDA) for SER120 (desmopressin nasal spray; Allergan and Serenity). In addition, the Committee voted 17-1 regarding the evidence in favor of at least one of the doses being effective.
OnabotulinumtoxinA treatment is safe and effective for long-term treatment of overactive bladder syndrome, according to a study published in the September issue of The Journal of Urology.
Analytica announced that the Food and Drug Administration (FDA) has approved PeriCoach at-home pelvic floor trainer device and smartphone app as an over-the-counter (OTC) treatment for mild, moderate, and stress urinary incontinence (UI) and urge incontinence.
Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) do not appear to significantly impact nocturnal urinary frequency, researchers from Albany Medical College, Albany, NY, reported.
A nasal spray may provide relief for patients struggling with nocturia, while other research highlights the positive benefits of exercise on the condition.
For older adults starting antimuscarinic treatment for overactive bladder (OAB), potentially inappropriate medication (PIM) use is highly prevalent and associated with greater total costs.
An app produced by the Interstitial Cystitis Network (ICN) may bring some relief to patients with urinary disorders looking to avoid foods that may provoke the pain and discomfort of their condition.
llergan announced results from an extension study of two Phase 3 trials on the long-term safety and efficacy of Botox (onabotulinumtoxinA) in female patients with overactive bladder (OAB) with symptoms of urge urinary incontinence.
Noninvasive erbium:yttrium-aluminum-garnet (Er:YAG) laser treatment appears promising for stress urinary incontinence (SUI) in women.
The Food and Drug Administration (FDA) has approved changes to the Myrbetriq (mirabegron; Astellas Pharma) label to include a new contraindication and a new update to the Warnings and Precautions section.
An intervention review indicates that mid-urethral sling (MUS) operations are a highly effective treatment for stress urinary incontinence (SUI) in women; however, complication rates and long-term need for repeat surgery are factors for patients to consider when choosing a procedure.
The PeriCoach System is now available to strength and tone pelvic muscles in women with urinary incontinence following its approval in March 2015.
For women with overactive bladder, medications delivered as a daily dose correlate with small reductions in urge incontinence episodes and voiding, according to a review published in Obstetrics & Gynecology.